TABLE 4

Time to Next Treatment

				Time to next treatment (mo)
Histologic characteristic	No. of patients	Progression/relapse (n)	Next treatment received (n)	Median	Range
Follicular lymphoma	13	8^*	7^†	6	2–44.5
Mantle cell lymphoma	14	14	12	9	1–26
Other lymphomas	4	3	3	4	2–17

↵* One patient was not evaluable.
↵† One patient had progression without indication for further therapy.